• 1. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 2. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 3. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 4. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 5. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053

Recent Advances in the Study of N-Isopropylnortropine Methobromide (Impurity) and Its Relevance to CAS 58005-18-8

N-Isopropylnortropine Methobromide (Impurity) is a critical compound in the field of pharmaceutical chemistry, particularly in the synthesis and quality control of tropane alkaloid derivatives. With the CAS number 58005-18-8, this impurity has garnered significant attention due to its potential impact on the efficacy and safety of pharmaceutical formulations. Recent studies have focused on its structural characterization, synthesis pathways, and analytical detection methods, aiming to ensure compliance with regulatory standards and improve drug purity.

One of the key findings in recent research is the development of advanced chromatographic techniques for the precise quantification of N-Isopropylnortropine Methobromide in drug substances. High-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS) has emerged as a gold standard, offering high sensitivity and specificity. These methods are crucial for identifying trace amounts of the impurity, which can otherwise compromise the therapeutic profile of the final drug product.

Another significant area of investigation involves the metabolic pathways and pharmacokinetics of N-Isopropylnortropine Methobromide. Studies have revealed that this impurity can interact with cytochrome P450 enzymes, potentially leading to altered drug metabolism. Understanding these interactions is essential for predicting drug-drug interactions and optimizing dosing regimens in clinical settings.

Furthermore, recent advancements in synthetic chemistry have enabled the development of more efficient routes for the production of N-Isopropylnortropine Methobromide, minimizing the formation of unwanted by-products. These synthetic improvements not only enhance the yield and purity of the compound but also reduce the environmental impact of pharmaceutical manufacturing processes.

In conclusion, the ongoing research on N-Isopropylnortropine Methobromide (Impurity) and its association with CAS 58005-18-8 underscores its importance in pharmaceutical development. The integration of advanced analytical techniques, metabolic studies, and synthetic optimizations is paving the way for safer and more effective drug formulations. Future studies should continue to explore the clinical implications of this impurity and its potential role in personalized medicine.

• 41447-16-9((+)-N-Methylallosedridine)
• 120-29-6(Tropine)
• 135-97-7(Pseudotropine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)